Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of study readout
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Tag: Readout
Readout Newsletter: Gilead, 23andMe, Argenx, RayzeBio
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Readout Newsletter: Abeona, Pfizer, Regeneron, AstraZeneca
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Readout Newsletter: Immunovant, Roivant, Sanofi, Regeneron
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Readout Newsletter: Neumora, Merck, Roche news
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Neumora’s antidepressant stumbles in first Phase 3 trial readout
A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial — the company’s first ...
Readout Newsletter: Keytruda, IRA, Pfizer, psychedelics
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your ...
Discover the latest in health and fitness with Your Health 247. Get expert advice, workout routines, healthy recipes, and mental wellness tips to lead a healthier, happier life. Stay informed and empowered with us!